Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

Author:

Richardson Paul G.1,Schjesvold Fredrik2ORCID,Weisel Katja3,Moreau Philippe4ORCID,Anderson Larry D.5,White Darrell6,Rodriguez‐Otero Paula7,Sonneveld Pieter8,Engelhardt Monika9ORCID,Jenner Matthew10,Corso Alessandro11,Dürig Jan12,Pavic Michel13,Salomo Morten14,Beksac Meral15,Oriol Albert16ORCID,Lindsay Jindriska17,Liberati Anna Marina18,Galli Monica19,Robak Pawel20,Larocca Alessandra21,Yagci Munci22,Vural Filiz23,Kanate Abraham S.24,Jiang Ruiyun25,Grote Lara25,Peluso Teresa26,Dimopoulos Meletios27ORCID

Affiliation:

1. Department of Medical Oncology Jerome Lipper Multiple Myeloma Center Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts USA

2. Oslo Myeloma Center at Oslo University Hospital KG Jebsen Center for B‐Cell Malignancies University of Oslo Oslo Norway

3. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology University Medical Center Hamburg‐Eppendorf Hamburg Germany

4. University Hospital Hôtel‐Dieu Nantes France

5. University of Texas Southwestern Medical Center Dallas Texas USA

6. Dalhousie University and Queen Elizabeth II Health Sciences Centre Halifax NS Canada

7. Clinica Universidad de NavarraCIMAIDISNA Pamplona Spain

8. Erasmus MC Cancer Institute Rotterdam The Netherlands

9. Universitätsklinikum Freiburg Freiburg Germany

10. Southampton General Hospital Southampton UK

11. Policlinico San Matteo Universita Di Pavia Pavia Italy

12. University Hospital Essen Essen Germany

13. Centre Hospitalier Universitaire De Sherbrooke (CHUS) Centre de Recherche Clinique Etienne‐Le Bel (CRCELB) Hopital Fleurimont Sherbrooke QC Canada

14. Copenhagen University HospitalRigshospitalet Copenhagen Denmark

15. Ankara University Ankara Turkey

16. Institut Català d'Oncologia I Institut Josep Carreras Hospital Germans Trias i Pujol Badalona Spain

17. East Kent Hospitals University NHS Foundation TrustKent and Canterbury Hospital Canterbury UK

18. University of Perugia Perugia Italy

19. Ospedale Papa Giovanni XXIIIU.O. di EmatologiaIspedali Riuniti di Bergamo Bergamo Italy

20. Medical University of Lodz Lodz Poland

21. A.O.U. Citta della Salute e della Scienza di Torino Torino Italy

22. Gazi University Medical Faculty Ankara Turkey

23. Ege University Izmir Turkey

24. West Virginia University Morgantown West Virginia USA

25. Bristol Myers Squibb Princeton New Jersey USA

26. Celgene International Sàrl, a Bristol‐Myers Squibb Company Boudry Switzerland

27. National and Kapodistrian University of Athens Athens Greece

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Hematology,General Medicine

Reference40 articles.

1. Treatment of relapsed and refractory multiple myeloma

2. New Treatment Options for the Management of Multiple Myeloma

3. Treatment of multiple myeloma in elderly patients: a review of literature and practice guidelines;Manapuram S;Cureus,2018

4. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

5. Multiple myeloma in the very elderly patient: challenges and solutions;Willan J;Clin Interv Aging,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3